Navigation Links
Cambrex Reports Fourth Quarter and Full Year 2009 Results
Date:2/10/2010

ables, loss on disposition of assets, cancellation or delays in renewal of contracts, lack of suitable raw materials or packaging materials, the Company's ability to receive regulatory approvals for its products and other factors described under the caption "Risk Factors That May Affect Future Results" in the Company's Quarterly Report on Form 10-Q for the period ending September 30, 2009.  Any forward-looking statement speaks only as of the date on which it is made, and the Company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise.  New factors emerge from time to time and it is not possible for the Company to predict which will arise.  In addition, the Company cannot assess the impact of each factor on its business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements.

For further details and a discussion of these and other risks and uncertainties, investors are cautioned to review the Cambrex 2008 Annual Report on Form 10-K, including the Forward-Looking Statement section therein, and other filings with the U.S. Securities and Exchange Commission.  The Company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise.

About Cambrex

Cambrex provides products and services to accelerate the development and commercialization of small molecule therapeutics including APIs, advanced intermediates, enhanced drug delivery, and other products for branded and generic pharmaceuticals.  The Company currently employs approximately 850 people worldwide.  For more information, please visit

SOURCE Cambrex Corporation
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15

Related biology technology :

1. Cambrex Presentation at the JPMorgan Healthcare Conference to be Webcast
2. Cambrex to Announce Fourth Quarter and Full Year 2007 Financial Results on February 14, 2008
3. Cambrex Appoints Steven M. Klosk as President and CEO
4. Cambrex Reports Third Quarter 2008 Results
5. Cambrex Receives Notice Regarding NYSE Listing
6. Cambrex Reports First Quarter 2009 Results
7. Cambrex Continuous-Flow Microwave-Assisted Organic Synthesis Technology Nominated for 2009 Innovations Award
8. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
9. QMed, Inc. Reports July Medicare SNP Enrollments
10. Phlo Affiliate Reports Expanded Coverage to Oregon Border
11. Healthcare Technologies Reports Loss for 2007 Second Quarter & Six Months Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/29/2015)... , June 29, 2015 ... and medical information products and services, today announced the ... According to the 2014 Journal Citation Reports® (JCR) published ... Impact Factors increase from 2013 to 2014, ahead of ... occupied the top rank in 62 subject categories, up ...
(Date:6/26/2015)... , June 26, 2015   ... ), a pet therapeutics company focused on ... biopharmaceutical products for companion animals, today announced ... study of capromorelin (AT-002), the company,s innovative ... is a small molecule that mimics ghrelin, ...
(Date:6/26/2015)... , ... June 26, 2015 , ... ... of Agriculture (USDA), Grain Inspection, Packers and Stockyards Administration (GIPSA) awarded a five ... vomitoxin in feed and grains utilizing Charm’s ROSA DONQ-FAST5 Test. This 5 minute ...
(Date:6/26/2015)... YORK and MUMBAI, India ... (BSE: 532540, NSE: TCS) a leading global IT services, ... been designated as a Leader in Worldwide Life Sciences ... in the " IDC MarketScape: Worldwide Life Science R&D ... report. The report evaluated eight leading ...
Breaking Biology Technology:Elsevier Announces 2014 Citation Impact Highlights 2Elsevier Announces 2014 Citation Impact Highlights 3Aratana Therapeutics Announces Positive Pivotal Results for AT-002 2Aratana Therapeutics Announces Positive Pivotal Results for AT-002 3Aratana Therapeutics Announces Positive Pivotal Results for AT-002 4Aratana Therapeutics Announces Positive Pivotal Results for AT-002 5USDA-GIPSA (FGIS) Awards 5 Year Contract for Vomitoxin Tests to Charm Sciences 2TCS Recognized as a Leader in Life Sciences R&D Risk-Based Monitoring by IDC MarketScape 2TCS Recognized as a Leader in Life Sciences R&D Risk-Based Monitoring by IDC MarketScape 3TCS Recognized as a Leader in Life Sciences R&D Risk-Based Monitoring by IDC MarketScape 4
... 5, 2012  PharmAthene, Inc. (NYSE Amex: PIP ), ... threats, announced today that management will present at the ROTH ... 2012 at 5:30 pm PT at the Ritz-Carlton Laguna Niguel ... ConferenceDate : , Monday, March 12, 2012 at 5:30 pm ...
... difference between salt water and fresh water is most ... bicarbonate salt solution, Penn State researchers can combine bacterial ... salt-water fresh-water gradient to produce power anywhere. "We ... them together," said Bruce E. Logan, Kappe Professor of ...
... -- FirstMark, the diagnostic division of GenWay Biotech, announced ... was held today on March 1, 2012. The Board ... research. The main focus of the Board will be ... of FirstMark,s new cardiovascular test PREvent. PREvent is the ...
Cached Biology Technology:Unique salt allows energy production to move inland 2Inaugural Meeting of the FirstMark Scientific Board of Advisors 2Inaugural Meeting of the FirstMark Scientific Board of Advisors 3
(Date:6/8/2015)... SAN DIEGO , June 8, 2015  Trovagene, Inc. ... announced today that clinical data featuring its Precision Cancer Monitoring ... Cancer Markers and Liquid Biopsies conference in San ... the AACR Precision Medicine Series: Integrating Clinical Genomics and ... on June 13-16. "We continue ...
(Date:6/5/2015)... GERMANTOWN, Md. , June 5, 2015  Intrexon ... synthetic biology, today announced that it has determined the ... of all of its 17,830,305 shares of ZIOPHARM Oncology, ... or about June 12, 2015, the distribution date, as ... stock, and on warrants to purchase shares of Intrexon ...
(Date:6/1/2015)... -- According to a new market research ... (Touch-based & Touchless), Application (Consumer Electronics, Automotive, & Others), ... Global Forecast to 2020", published by MarketsandMarkets, the Gesture ... $23.55 Billion by 2020, at a CAGR of 28.23% ... market data T ables and   86   ...
Breaking Biology News(10 mins):Clinical Data Featuring Trovagene's Urine-Based Liquid Biopsy Platform to be Presented at Two Upcoming Medical Conferences 2Clinical Data Featuring Trovagene's Urine-Based Liquid Biopsy Platform to be Presented at Two Upcoming Medical Conferences 3Clinical Data Featuring Trovagene's Urine-Based Liquid Biopsy Platform to be Presented at Two Upcoming Medical Conferences 4Intrexon Announces Distribution Ratio for Distribution of ZIOPHARM Shares 2Intrexon Announces Distribution Ratio for Distribution of ZIOPHARM Shares 3Intrexon Announces Distribution Ratio for Distribution of ZIOPHARM Shares 4Gesture Recognition & Touchless Sensing Market Worth $23.55 Billion by 2020 2Gesture Recognition & Touchless Sensing Market Worth $23.55 Billion by 2020 3Gesture Recognition & Touchless Sensing Market Worth $23.55 Billion by 2020 4
... liver disease, extent of tissue damage depends on the balance ... new liver cells. In a significant minority of people who ... form scars. This can progress to chronic liver disease and ... unable to clean blood or produce vital hormones and clotting ...
... a type of cell that can be activated by tissues ... attack our own molecules, cells and organs, UCSF researchers have ... new strategies for fighting a range of autoimmune diseases ... and cells within us as well as for preventing ...
... CHICAGO A low-calorie diet eliminates insulin dependence ... with type 2 diabetes, according to a study presented ... of North America (RSNA). "Lifestyle interventions may have ... patients," said the study,s lead author, Sebastiaan Hammer, M.D., ...
Cached Biology News:The immune system has protective memory cells, researchers discover 2The immune system has protective memory cells, researchers discover 3Restricted calorie diet improves heart function in obese patients with diabetes 2
HybriWell seals securely to a microscope slide surface in seconds to enclose single or multiple specimens in a small reagent volume and eliminate evaporation....
Comp Dim: chamber diam. depth 20 2.8 mm chamber maximum volume 720 μL...
... Human IgM Assay Kit to address the ... assay for Human IgM that eliminates the ... a simple mix-and-read assay that allows the ... ng/ml in approximately 30 minutes. The Pierce ...
AC input: 230 V...
Biology Products: